Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
关于绿康生化股份有限公司2025年年报问询函相关问题之专项核查意见
Regulatory Filings Classification · 85% confidence The document is a special verification opinion (专项核查意见) issued by a law firm in response to an inquiry letter from the Shenzhen Stock Exchange concerning the company’s 2025 Annual Report. It does not contain the financial statements themselves but serves as a legal attestation and compliance confirmation. Under the classification rules, such officer certifications or legal opinion letters fall under Regulatory Filings (RNS), rather than being classified as the Annual Report or Audit Report.
2026-05-11 Chinese
绿康生化股份有限公司关于对2025年年报问询函回复的公告
Regulatory Filings Classification · 90% confidence The document is a public announcement titled “关于对2025年年报问询函回复的公告,” in which the company formally responds to an inquiry letter from the Shenzhen Stock Exchange concerning its 2025 annual report. It is not the annual report itself (no full financial statements), nor an earnings release or management presentation; rather, it is a regulatory disclosure filing of the company’s written reply. This falls under the general “Regulatory Filings” category.
2026-05-11 Chinese
关于公司股票交易撤销退市风险警示及其他风险警示暨股票停复牌的公告
Regulatory Filings Classification · 85% confidence The document is a corporate stock trading announcement regarding the removal of delisting and risk warnings, suspension and resumption of trading, and change of stock abbreviation and daily price limits. It does not constitute an interim or annual financial report, audit report, dividend notice, share issue, or any of the specialized categories. It is a routine regulatory disclosure of stock trading status under exchange rules, fitting the fallback category of a general regulatory filing.
2026-05-11 Chinese
关于持股5%以上股东股份解除冻结的公告
Major Shareholding Notification Classification · 85% confidence The document is a formal corporate announcement disclosing that a shareholder holding over 5% of the company’s stock has had a portion of its shares unfrozen. It provides details on the amount released, dates, and remaining share status. This type of filing corresponds to notifications around significant shareholding events. There is no category for share freeze/unfreeze specifically, but “Major Shareholding Notification” (MRQ) covers disclosures involving >5% shareholding changes. Thus, MRQ is the best fit.
2026-05-11 Chinese
立信会计师事务所（特殊普通合伙）关于对绿康生化股份有限公司2025年年报问询函的专项说明
Regulatory Filings Classification · 85% confidence The document is a detailed response from the company’s auditors to an inquiry letter issued by the Shenzhen Stock Exchange regarding the 2025 annual report. It is not the annual report itself, nor a standalone audit report, earnings release, or shareholder meeting material. Rather, it is a regulatory compliance filing—an explanatory reply to the regulator’s questions. Therefore, it best fits the catch-all “Regulatory Filings” category.
2026-05-11 Chinese
第五届董事会第三十四次（临时）会议决议公告
Board/Management Information Classification · 80% confidence The document is a Chinese board resolution announcement (meeting notice and resolutions of the Fifth Board’s 34th (extraordinary) meeting) covering approval of the Q1 report and appointment/resignation of the securities affairs representative. It is not the full quarterly report itself, nor an earnings release, but rather a board/management information disclosure (board meeting resolutions, including management appointment). Therefore, it matches the Board/Management Information category (MANG).
2026-04-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.